Clinical Trial Update: A Study of Belimumab Administered Subcutaneously in Subjects With Systemic Lupus Erythematosus (SLE) [Phase 3]

View source ↗

Summary

A Phase 3 study evaluating subcutaneous belimumab in systemic lupus erythematosus has completed, with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Systemic Lupus Erythematosus

Drugs mentioned

• Belimumab (belimumab)

Snippet

Sponsor: Human Genome Sciences Inc., a GSK Company | Conditions: Systemic Lupus Erythematosus | Phase 3 | Status: COMPLETED | Results posted: 2017-07-25